^
    Back
    Association details:
    Biomarker:ALK S1206Y
    Cancer:Non Small Cell Lung Cancer
    Drug:Xalkori (crizotinib) (ALK inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Transl Cancer Res
    Title:

    Molecular resistance mechanisms of ALK inhibitors and implications for therapeutic management of ALK-rearranged lung cancer patients

    Published date:
    02/24/2017
    Excerpt:
    In this study crizotinib resistance mutations were confirmed in 11 (20%, N=51) specimens from biopsy sites that included pleural fluid (31%), liver (22%), and nodal tissue (18%) from 10 patients….Other mutations (frequency) detected were C1156Y (2%), G1202R (2%), I1171T (2%), S1206Y (2%), and E1210K (2%).
    DOI:
    10.21037/tcr.2017.03.22